Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD)

/PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers,...

Related Keywords

Brisbane ,Queensland ,Australia ,Joseph Dal Porto ,Karim Dabbagh ,Colitis Organization ,Arena Pharmaceuticals ,Drug Administration ,Gilead Sciences Inc ,European Crohn ,Chief Executive Officer ,Second Genome ,Chief Science Officer ,Virtual Plenary Hall ,Mucosal Healing ,Gilead Sciences ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Surveys ,Olls And Research ,Clinical Trials Amp Medical Discoveries ,Roadcast Feed Annoucement ,